

Integrated Bioinformatic Approach for Precision Medicine: Prediction of Human GABRG2 Gene Pathogenic Variants, Characterized with Cellular Pathology and Epilepsy Phenotype Severity

Nabaa Khudhair ABDULLAH¹ , Ayla ARSLAN^{2*} 

¹ Üsküdar Üniversitesi, Fen Bilimleri Enstitüsü, 34662, İstanbul, Türkiye

² Üsküdar Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümü, 34662 İstanbul, Türkiye

(Alınış / Received: 22.11.2023, Kabul / Accepted: 30.08.2024, Online Yayınlanma / Published Online: 23.12.2024)

Keywords

GABA (A) receptor
Gamma-2 subunit
Epilepsy
Precision medicine
Pathogenic variant
In silico

Abstract: Encoding for the $\gamma 2$ subunit of inhibitory GABA (A) receptors, GABRG2 gene expression is widespread in the brain including cortex, hippocampus, cerebellum and nuclei of brainstem. Pathogenic variants of GABRG2 have been associated with epilepsy syndromes however, the difficulty in interpreting GABRG2 variants of unknown significance hinders the advancement of epilepsy precision medicine. Using computer algorithms, our study focused on 156 GABRG2 variants of unknown significance from ClinVar database, predicting 10 highly pathogenic variants within the $\gamma 2$ ($\gamma 2S$ isoform) subunit. Integration with patient mutations and mutagenesis studies locates these variants within 'epileptogenic structural cassettes' of the $\gamma 2$ subunit, aiding characterization of phenotype severity and cellular pathology. Our results predict milder phenotypes for N-terminus extracellular domain variants (S155F, C190F, M199T) and more severe phenotypes for transmembrane domain variants (Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C), linked to cellular pathology with reduced cell surface expression and reduced cell current. Notably, 4 transmembrane domain variants (G308D, T310I, T314K, T317S in the receptor's pore-lining M2 region) may distort channel conductance. Our research aligns with ACMG/AMP criteria PP3.

Hassas Tıp için Bütünleşik Biyoinformatik Yaklaşım: İnsan GABRG2 Geninin Hücre Patolojisi ve Epilepsi Fenotip Şiddeti ile Karakterize Patojenik Varyantlarının Tahmini

Anahtar Kelimeler

GABA (A) reseptörü,
Gama-2 alt birimi,
Epilepsi
Hassas Tıp,
Patojenik varyant,
In silico

Özet: GABA(A) reseptörlerinin $\gamma 2$ alt birimini kodlayan GABRG2 geninin ifadesi, korteks, hipokampus, serebellum ve beyin sapı çekirdekleri dahil olmak üzere beyinde geniş bir alana yayılmıştır. GABRG2 geninin patojenik varyantları epilepsi sendromları ile ilişkilendirilmiştir, ancak bilinmeyen öneme sahip GABRG2 varyantlarını yorumlamanın zorluğu, epilepsiye yönelik hassas tıbbın ilerlemesini engel teşkil etmektedir. Bilgisayar algoritmaları kullanılarak yapılan çalışmamızda, ClinVar veritabanındaki klinik önemi bilinmeyen 156 GABRG2 geni varyantına odaklanıldı ve $\gamma 2$ ($\gamma 2S$ izoformu) alt biriminde bulunan 10 varyant patojenik olarak tahmin edildi. Hasta mutasyonları ve mutagenез çalışmalarıyla entegrasyon sonucunda varyantların $\gamma 2$ alt biriminde 'epileptojenik yapısal kasetler' içinde konumlandırılmasıyla, fenotip şiddeti ve hücresel patoloji karakterize edildi. 3 tane N-terminus ekstrasellüler bölge varyantı (S155F, C190F, M199T), az şiddetli ve 7 tane transmembran bölge varyantı (Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C) daha şiddetli epilepsi fenotipleri ile beraber azalmış hücre yüzeyi ifadesi ve azalmış hücresel akımla bağlantılı olarak öngörüldü. Özellikle, 4 transmembran bölge varyantının (Reseptörün kanal poruna katkıda bulunan M2 bölgesindeki G308D, T310I, T314K, T317S) kanal iletkenliğini bozabileceği belirlendi. Araştırmamız, ACMG/AMP kriterlerinden PP3 ile uyumludur.

* Corresponding author: ayla.arslan@uskudar.edu.tr

1. Introduction

Critical for the regulation of spike timing and modulation of neuronal rhythms, GABAergic interneurons appear to have an important role in brain information processing [1–4]. This depends on the precise matching of input signals from the diverse repertoire of GABAergic interneurons, with their molecular counterparts, the Gamma-Aminobutyric acid type A receptors (GABA_ARs)[5–9], located in distinct zones of the postsynaptic and extrasynaptic membrane [10–14]. This differential localization, along with other diverse features of receptor subtypes have specific physiological functions important during health and disease [15–20]. Thus, any alteration in the assembly, trafficking and cell surface expression of GABA_ARs may cause the deterioration of the GABAergic process, posing a risk for a wide variety of psychiatric and neurological disorders [13,21–26], including epilepsy[27], a complex neurological condition characterized by recurrent unprovoked seizures [28].

Assembled from a large subunit pool (α 1-6, β 1-3, γ 1-3, δ , ϵ , θ , π , ρ 1-3), GABA_ARs are GABA gated heteropentameric chloride channels and primary sites for brain inhibition[21]. They are composed of five subunits, with the prevalent subtypes typically consisting of two α subunits, two β subunits, and one γ 2 subunit [21]. In recent years, advancements in cryo-electron microscopy (cryo-EM) have driven a series of breakthroughs in the structural biology of GABA_ARs [16,29–35]. The receptor has a cylindrical shape, formed by the spatial arrangement of subunits such as β - α - β - α - γ in the counter-clockwise direction when observed from the extracellular space [22]. Of particular significance is the human γ 2 subunit [37–39], which is encoded by the GABRG2 gene located on chromosome 5q34 [21]. The γ 2 subunit containing receptors mediate fast phasic inhibition [15]. This subunit exhibits significant expression in both developing and mature brain and about 60% of all GABA_ARs coassembly constitutes the γ 2 subunit [40]. Studies of heterozygous γ 2 knockout mice have shown a 25% reduction in γ 2 subunits in the cerebral cortex, hippocampus, and thalamus, accompanied by decreased clustering of GABA_ARs and increased anxiety [41]. In addition, these mice display absence-like spike-wave discharges, mild epilepsy, and altered biogenesis of the remaining wild-type γ 2 subunits [42–44]. The γ 2 subunit plays vital roles in various aspects of GABA_AR function, such as clustering, synaptic maintenance, and current kinetics [37–39,45,46]. Indeed, via specific subunits GABA_ARs have specific assembly rules, membrane localization, receptor clustering, pharmacology and plasticity [47–52,37,38,53–55,36,56]. These properties may be altered by numerous inherited or de novo mutations, which have been discovered in genes encoding the GABA_AR subunits, including the GABRG2 gene, associated with a wide range of epilepsy conditions

manifesting mild to severe phenotypic features [57–62,26,63]. By binding at the specific sites located in the GABA_ARs subunit domains or subunit interfaces, many clinical central nervous system (CNS) drugs function by enhancing GABA_AR mediated inhibition[56]. For instance, Phenobarbital has been used to treat epilepsy for more than 100 years[64,65]. Phenobarbital binds to the γ - β interface and α - β interface[66].

Genetic testing is an integral component of epilepsy diagnosis [67,68]. However, in recent years, the genetic testing performed by next generation sequencing has led to the accumulation of variants of unknown significance (VUS), necessitating their interpretation [69]. Consequently, American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) have established a framework for interpreting the clinical significance of genetic variants [70]. This framework categorizes the variants as “Pathogenic”, “Likely pathogenic”, “Uncertain significance” “Benign”, or “Likely benign” [70]. According to this framework, in silico methods, which use computational predictions to assess variant effects, are considered as supporting evidence for pathogenicity, corresponding to criterion PP3 [70]. Accumulating literature show successful integration of VUS, interpreted as damaging or deleterious by in silico methods [71,72], into the system of epilepsy diagnosis and management [68,72–74]. Given the importance of the GABRG2 gene variants described so far, this study specifically focuses on the comprehensive in silico analysis of the VUS detected in the coding region of the γ 2 subunit. Through this analysis, the potential impact of these VUS on protein structure and function is assessed and elaborated through the integration with the data from the epilepsy patient mutations.

2. Material and Method

Methods are given in the **Appendix A**.

3. Results

3.1. Workflow

The structured analysis comprises several steps as detailed in **Figure 1**. Initially, GABRG2 variants were accessed from NCBI ClinVar database [75]. These variants underwent comprehensive assessment using a set of algorithms, namely SIFT[76], PANTHER [77], Polyphen-2 [78], PhD-SNP [79], and SNPs&GO [80]. These algorithms utilized a homology based analysis (expect for the PolyPhen2, which is based on both sequence and structural parameters)[71]. Following this, functional and stability analysis was performed with the help of MutPred2 [81] and I-Mutant 2.0 [82]. Evolutionary conservation scores were obtained via ConSurf algorithm [83–85] to gauge residue importance leading to the selection of 20 VUS, which

were then subjected to three-dimensional (3D) structural modeling for validation. The results (10 variants) were integrated with structural, functional data, in addition to epilepsy patient data from the literature.




Figure 1. The general overview of the study.

3.2. Data mining

The variant data of GABRG2 transcript variant 2, encoding for the shorter isoform of the $\gamma 2$ subunit (or $\gamma 2S$) were classified according to classification criteria of ClinVar database [75]. This classification is based on the ACMG/AMP variant classification system [70] and other standards (<https://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/#standard> accessed 10.07.2024). As seen in the Figure 2.A, a total of 588 GABRG2 variants are classified according to “Clinical significance”, “Molecular consequence”, and “Variation type”. Among them, 494 are “Single Nucleotide Variants”, and the rest include “Deletions” (64), “Duplications” (28), and “Insertions” (14). In terms of “Molecular consequence”, there are 207 variants in untranslated regions or “UTRs”, 24 are “Nonsense” variants, 18 are “Splice site” and 16 are “Frameshift”. Almost half of the variants are missense (494) among the all variants (45 %, Figure 2.B). In the category of “Clinical significance”, there are 156 “Missense” variants with “Uncertain significance” (VUS), as well as 14 variants, categorized as “Likely benign”, 5 “Benign” variants, 12 “Pathogenic” variants, 16 “Likely pathogenic” variants, and 15 variants with “Conflicting interpretations” as shown in Figure 2.B.




Figure 2. Profile of GABRG2 gene variants (A) Classification of GABRG2 variants according to three

categories: “Clinical significance”, “Molecular consequence” and “Variation type”. (B) The categorization of missense variants, which constitute 45% of all GABRG2 variants, is based on their “Clinical significance”, namely “Uncertain significance”, “Likely benign”, “Benign”, “Likely pathogenic”, “Pathogenic”, and ‘Conflicting interpretation’.

3.3. Homology-based prediction of pathogenicity for GABRG2 variants

The 156 GABRG2 VUS (Appendix B, ClinVar) were evaluated using SIFT [76], PolyPhen-2 [86], PANTHER [77], PhD-SNP [79], and SNPs&GO [80]. (SIFT found 80 deleterious variants with a score ≤ 0.05 , while PolyPhen-2 marked 66 as probably damaging (scores close to 1). PANTHER [77] identified 126 as Likely damaging based on evolutionary conservation. PhD-SNPs [79] predicted 84 as Disease, and SNPs&GO labeled 57 as Disease. SNPs&GO had the highest number of Benign predictions (98), followed by SIFT (76), PhD-SNP (72), and PolyPhen2 (60). Additionally, PANTHER [77] and PolyPhen2 [86] identified 30 and 29 Likely pathogenic variants, respectively. It is important to note that the variant classification terms used in the prediction tools are dissimilar and do not correspond to the terms of 5-tier ACMG system [70]. For instance “Pathogenic” which is the classification category in ClinVar

(<https://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/#standard> accessed 12.07.2024) is based on ACMG system [70]. It represents clinically validated category with comprehensive evidence and may be used for direct medical decision-making. For clarity, this and other ClinVar variant classification categories are shown with double quotation marks (“...”) in the entire manuscript. However when a prediction tool classifies a variant as ‘Pathogenic’, ‘Disease’, ‘Damaging’, or ‘Deleterious’, it is an algorithm-based prediction suggesting potential harm, requires further validation by additional evidence and clinical correlation to be used in decision-making. Therefore, in this manuscript, only ClinVar categories were written with double quotation (“...”) marks. In contrast, other terms, specifically in silico prediction terms, were capitalized as proper nouns or, if they were not terms but adjectives, they were written in lowercase, such as the adjective ‘pathogenic’. The algorithmic prediction results presented in the Figure 3 summarizes the classification under three categories: Deleterious, Possibly damaging, and Neutral, which represent classifications of in silico assessments (SIFT [76], PolyPhen-2 [86], PANTHER [77], PhD-SNP [79], and SNPs&GO [80]). To identify the most pathogenic variants, a filter was applied: variants had to meet specific criteria, including being predicted as damaging or intolerant by at least four tools, with a SIFT score of 0 and a PolyPhen2 score of 1. This filter identified 28 pathogenic variants (L81F, P83T, R125H, D149H, F152S, S155F, M199T, C190F,

E217G, Y220C, Y280D, V292G, G308D, I309T, I309M, T310I, I313M, T314K, T317S, V329F, Y331N, D336G, C342Y, R446C, F453L, N457Y, Y460C, and W461R). These variants are given in the **Appendix C Table 1**, together with ClinVar accession and version numbers. These variants scored 0 in SIFT, 1 in PolyPhen2, and were predicted as Probably damaging and Disease by PANTHER [77]. PhD-SNP [79] also categorized them as Disease while SNPs&GO [80] classified all as Disease, except for L81F, I309T, I309M, and L313M, which were considered Neutral.




Figure 3. Deleterious, Neutral and Possibly damaging variants of GABRG2 predicted by five in silico tools (SIFT [76], PolyPhen2, PANTHER [77], PhD-SNP and SNPs&GO [80]).

The identified 28 deleterious or pathogenic GABRG2 gene variants are mapped to the corresponding protein domains [87] of the $\gamma 2$ subunit. In the NCBI database (RefSeq: NP_000807.2), this 467 amino acid long subunit is characterized with a signal peptide between the residues 1-39, N terminus extracellular domain (ECD) between the residues 90 and 271, first transmembrane domain (M1) between the amino acids 274-296, second transmembrane domain (M2) between the residues 300-322, third transmembrane domain (M3) between the residues 334 and 356, fourth transmembrane domain (M4) spanning from the amino acid residue from 444 until the 466. In addition, it has an intracellular domain (ICD) in between the residues 357-443, where it interacts with GABA(A)-receptor-associated protein (GABARAP) [88] in the region between the residues 425 and 442. The 10 of the variants, predicted as pathogenic, are located within the ECD (L81F, P83T, R125H, D149H, F152S, S155F, M199T, C190F, E217G and Y220C), two in the M1 (Y280D & V292G), 7 in the M2 (G308D, I309T, I309M, T310I, I313M, T314K, T317S), 2 variants in the linker between the M2-M3 (V329F & Y331N), 2 in the M3 (D336G & C342Y), and 5 in the M4 region (R446C, F453L, N457Y, Y460C, W461R). Specificities of these variants are summarized in **Appendix C Table 2**.

3.4. Functional and stability analysis

3.4.1. Analysis of variant effects: Molecular mechanisms

The MutPred2 [81] server is used to investigate variant impact on molecular mechanisms of $\gamma 2$ subunit. To predict the relevant molecular mechanisms, the identified 28 variants were studied by submitting the amino acid sequence of GABRG2 Isoform 2 (RefSeq NM_000816.3 and NP_000807.2, NCBI database [89]) to Mutpred2 server [81]. MutPred2 is based on the machine learning approach that combines genetic and molecular data to assess the likelihood of amino acid substitutions being pathogenic. It works by offering two key features: a general prediction of pathogenicity and a ranked list of specific molecular changes that could potentially impact the phenotype. The method is trained on a dataset comprising 53,180 pathogenic variants and 206,946 unlabeled variants (assumed to be neutral) sourced from the Human Gene Mutation Database (HGMD) [90], SwissVar [91], dbSNP [89], and inter-species pairwise alignment. MutPred2 follows a series of steps to assess the impact of a substitution on protein structure and function. Mutpred2 data sets were developed for the training of various property predictors that rely on public data with different dates. For instance, protein-protein interaction datasets date back to 2012 [81]. On the other hand, the GABA_AR structural data, which also present the subunit interaction interfaces for instance, have been published only recently [30,32]. Thus, for supporting evidence, the Mutpred2 results were integrated with the recent evidence from the literature (NCBI [89] and PDBe [92,93]) and described in the Supplementary File for MutPred Analysis (**Appendix B, MutPred**) that involves the recent structural data of GABA_AR subunits [30]. This approach does not only allow a comprehensive analysis but also an opportunity to test the accuracy of the MutPred2 results.

The general score of MutPred2 [81] prediction for the 28 variants of the $\gamma 2$ subunit is presented in the **Table 3**, which shows that all the 28 variants (L81F, P83T, R125H, D149H, F152S, S155F, C190F, M199T, E217G, Y220C, Y280D, V292G, G308D, I309T, I309M, T310I, L313M, T314K, T317S, V329F, Y331N, D336G, C342Y, R446Q, F453L, N457Y, Y460C, W461R) have a high probability of pathogenicity with a score higher than 0.75. Additional scores including Property score (Probability) and P value as well as the mechanisms for the pathogenicity can be found in **Appendix B, MutPred**. The property score, which ranges from 0 to 1, represents the probability of loss or gain of the specific property due to the substitution. A higher property score suggests that the alteration of that property is more likely to be involved in the molecular mechanism of the associated disease. Reflecting on these, the variant L81F has a MutPred2 [81] score 0.818. Among the candidate molecular mechanisms with a p value < 0.05, 'Altered ordered

interface' has the highest probability (0.31) (P value = 0.01). Additionally, mechanism of 'Altered transmembrane protein' (Probability score is 0.27, P value is 0.00082) was predicted. This is well reflected by structural studies: when we identified variants predicted to be pathogenic, we primarily observed that they corresponded to critical amino acid positions, and predominantly involved interface interactions. **Appendix C, Table 4** lists these residues found in the receptor subunit interaction interfaces. Interestingly, L81 is in the ECD interface of the $\gamma 2$ subunit interacting with $\beta 2$ or $\beta 3$ subunits as described in Cryogenic electron microscopy (cryoEM) structures of human GABA_AR [30,32](**Appendix C, Table 4**). Thus, the impact of L81F will likely be the distortion of interaction of the $\gamma 2$ subunit with β subunits leading to the alteration of receptor oligomerization. The significance of ECD was demonstrated by a point mutation (R43Q) found in the $\gamma 2$ subunit, which is linked to childhood absence epilepsy and febrile seizure[94]. The ECD consists of an N-terminal α -helix followed by a core β sandwich composed of 10 β strands, with the GABA-binding site located near the middle of the ECD. Studies show that receptor assembly process, which starts in the endoplasmic reticulum (ER), is primarily regulated by the N-terminal ECD of the subunits[95]. N-terminal deletions in the $\gamma 2$ subunit impaired its incorporation into receptors [96]. Consequently, when interpreting the MutPred2 prediction, we will examine the ECD variants from this perspective. In addition to L81F, there are 9 more variants in the ECD: P83T, R125H, D149H, F152S, S155F, C190F, M199T, E217G, Y220C. Among these P83T, which has MutPred2 score of 0.895 was predicted as 'Altered ordered interface' (probability score 0.29, p value 0.03) and 'Altered transmembrane protein' (probability score 0.28, p value 0.00067) (**Appendix B, MutPred**).

Like L81, the P83 is in the ECD interface of the $\gamma 2$ subunit interacting with $\beta 2$ or $\beta 3$ subunits as shown in cryoEM structures of human GABA_ARs [30,32] (**Appendix C, Table 4**). Thus, the variant P83T, which is located in the α - $\beta 1$ loop of the $\gamma 2$ subunit at $\gamma 2$ / $\beta 2$ - subunit interface, will pose the risk of altered interaction of the $\gamma 2$ subunit with β subunits leading to the alteration of receptor oligomerization. Indeed, another variant in the same position (GABRG2, P83S variant) was previously reported in a family with idiopathic generalized epilepsy, where it was observed to be associated with the seizure phenotype [97]. The mutant receptors with this variant had reduced cell surface expression owing to the altered receptor assembly and ER retention, decreased whole-cell current amplitudes and increased sensitivity to Zinc ions (Zn^{2+}), despite some inconsistent findings in the literature [62]. These likely confirm that the P83T identified in this study, may cause pathogenic effect. Similarly, the rest of the variants (R125H, D149H, F152S, S155F, E217G) and

their localization in the molecular interaction interfaces verify the prediction of 'Altered ordered interface' and 'Altered transmembrane protein' although these mechanisms are not necessarily have the highest MuPred2 [81] prediction probability (**Appendix B, MutPred**). For instance, D149H is described as 'Altered metal binding' (Probability score: 0.42) according to MupPred2 candidate mechanism for pathogenicity (MutPred2 score: 0.942, **Appendix B**). Zn^{2+} , the divalent metal cation, acts as non-competitive inhibitor of both $\alpha\beta$ and $\alpha\beta\gamma$ GABA_ARs [98,99] but the Zn^{2+} binding site is primarily found in the β subunit. According to structural analysis at 3.0 Å resolution, this site is formed by a group of three histidine residues positioned at amino acid position 267 within the pore lining M2 helices of $\beta 3$ subunits [100]. So 'Altered metal binding' effect of D149H in the $\gamma 2$ subunit is an unlikely mechanism although it has highest probability score among the candidate mechanisms (**Appendix B, MutPred**). Indeed, the distortion of the Zn^{2+} binding site, would not be expected as a mechanism relevant to epilepsy, since Zn^{2+} is an inhibitor of GABA_ARs[3].

On the other hand, 'Altered ordered interface' and 'Altered transmembrane protein' appears to be the possible mechanisms for pathogenic effect since D149 is a residue at the interaction interface with $\beta 2$ & $\beta 3$ subunits (**Appendix C, Table 4**). Same conclusions can be made for the other variants (C190F, M199T, E217G) in the ECD that "altered ordered interface" and 'Altered transmembrane protein' appears to be the possible MutPred2 predicted mechanisms (**Appendix B**) instead of 'Altered metal binding' since these ECD variants correspond to residues at the subunit interfaces (**Appendix C, Table 4**).

Taken together the mechanism of pathogenic effect of the seven ECD variants (L81F, P83T, R125H, D149H, F152S, S155F, E217G) is predicted as 'Altered ordered interface' and 'Altered transmembrane protein'. The remaining ECD variants, C190F, M199T and Y220C, will be examined separately since they do not correspond to subunit interface sites. The variant C190F is predicted as 'Altered metal binding site' (MutPred2 probability=0.6, **Appendix B, MutPred**). Similarly, M199T and Y220C are predicted as 'Altered metal binding sites' (MutPred2 probability scores are 0.29 and 0.57 respectively (**Appendix B, MutPred**). The mechanism of pathogenicity for these variants are unclear since there is not a significant metal (such as Zn^{2+}) binding site in the $\gamma 2$ subunit and supporting data are required for the proposition of molecular mechanism of pathogenicity in later sections of this study (protein modeling).

The other variants analyzed by MutPred2 are located in M1 domain (V292G) in addition to those in the M2

domain (I309T & I309M, T310I, L313M, T314K, T317S), D336G and C342Y in the M3, R446Q in M4 as well as the variants in the M2-M3 linker (V329F, Y331N). The Mutpred2 score of M1 variant V292G is 0.82. Among the candidate mechanisms for pathogenic effects of the G variant in the position of 292, are “Altered transmembrane protein”, “Altered ordered interface” and “Altered stability” (**Appendix B, MutPred**). Since these mechanisms are complementary each other and the variant V292G is located at the interaction interface with $\alpha 1$ & $\beta 3$ subunit (**Appendix C Table 4**), we conclude that pathogenic effect of this variant is predicted as ‘Altered ordered interface’ and ‘Altered transmembrane protein’. The M2 domain is the region for the pore lining of the receptor channel for chloride ion to pass through [21]. The M2 region plays a role in forming the ion channel pore of the receptor, allowing the passage of ions. On the other hand, the intracellular domain (ICD) located between M3 and M4 domains, contains sites where phosphorylation occurs and interacts with other proteins, thereby influencing the function and trafficking of the channel [3, 60, 61]. For the variants predicted as pathogenic in this region, ‘Altered stability’ or ‘Altered transmembrane protein’ has the highest probability for the mechanism of pathogenicity according to Mupred2 [81] (**Appendix B, MutPred**). In the M2 domain, the variants I309T and I309M are found in the subunit interaction interface between the $\gamma 2$ subunit and $\beta 2$ or $\beta 3$ subunits. The variant T314K is located at the subunit interaction interface of $\gamma 2$ subunit with $\alpha 1$ or $\beta 3$ subunits (**Appendix C, Table 4**). These residues do not correspond to any variants in the M2 region identified in this study. CryoEM studies determined structural coordinates of GABA_ARs that the chloride ion interacts with the residues V104, L237, Y238, Q239, F240 [34].

Interestingly, D336G in the M3 is predicted as loss of helix (P value ≤ 0.05) according to MutPred2 [81] analysis. This effect will likely cause an effect in the receptor integrity since it is located in the interaction interface with $\beta 2$ & $\beta 3$ subunits (**Appendix C, Table 4**). Also, the variants in the M2-M3 linker (V329F, Y331N) have the following properties: Val329 is located at the interaction interface with $\beta 2$ & $\beta 3$ subunits and Tyr331 is located at the interaction interface with $\beta 2$ subunits (**Appendix C, Table 4**). These results are well correlated with the Mutpred2 analysis that represents “Altered ordered interface” (P value ≤ 0.05) (**Appendix B, MutPred**). Thus, these residues will likely cause a molecular mechanism that will presumably impact on receptor assembly.

M4 of the $\gamma 2$ subunit is known to be critical for the postsynaptic targeting of the $\gamma 2$ subunit containing GABA_ARs. Initially, it was believed that the ICD of the $\gamma 2$ subunit played a crucial role in postsynaptic targeting[53]. However, research has revealed that

the localization $\gamma 2$ subunit containing GABA_ARs to postsynaptic sites primarily occurs through a mechanism that is mostly unrelated to the ICD of the $\gamma 2$ subunit [14,51,53]. Instead, it relies on the presence of the $\gamma 2$ subunit's C-terminal sequence, which includes the M4 [51]. Thus, the transmembrane domain (M4) —not the ICD as previously thought[14]—of the $\gamma 2$ subunit appears to be important for the membrane targeting of receptor subtypes[14,51]. We have identified R446Q, F453L, N457Y, Y460C, W461R as pathogenic in the this domain. According to MutPred2 [81] results, R446Q variant causes “altered ordered interface” (P value < 0.05). Indeed, structural data show that among the variants identified in this domain only R446Q is located at the subunit interaction interface of the receptor (**Appendix C, Table 4**). Thus, this molecular mechanism of this variant effect predicted by MutPred2 seems to be reasonable. For the remaining variants, Mutpred2 results suggest ‘Altered ordered interface’ and ‘Altered transmembrane protein’ as most probable mechanisms for the variants N457Y (MutPred2 score: 0.909, P value < 0.05), Y460C (MutPred2 score: 0.942, P value < 0.05) and W461R (MutPred2 score: 0.946, P value < 0.05) and the “altered transmembrane protein” for the F453L (MutPred2 score: 0.911, P value < 0.05) (**Appendix B and Appendix C Table 3**).

3.4.2. Stability prediction

The impact of the 28 variants on GABRG2 protein stability was predicted by I-Mutant2.0[82] web server. According to I-Mutant2.0, the 28 variants considered to decrease the stability of $\gamma 2$ subunit (except the S155F which predicted to increase the stability). The prediction conditions were 25 °C and PH=7, and the resulted DDG, which stands for the change in Gibbs free energy ($\Delta\Delta G$) due to the variant. This, and the reliability index (RI), a score that indicates the confidence level of the predicted DDG value, are presented in the **Figure 4**. DDG > 0 is associated with stabilizing effect while DDG < 0 is associated with the destabilizing mutation. The variants V929G (RI= 9, DDG= -3.98), V329F (RI=9, DDG= -3.59), D336G (RI=7, DDG= -2.16), F152S (RI= 9, DDG= -2.05) and E217G (RI=7, DDG= -2.04) show the highest destabilizing effect. Furthermore, the variants R125H (RI= 9, DDG= -1.71), F453L (RI= 8, DDG= -1.56), Y331N (RI= 4, DDG= -1.51), W461R (RI= 8, DDG= -1.48), M199T (RI= 7, DDG= -1.42), P83T (RI= 8, DDG= -1.33), D149H (RI= 7, DDG= -1.13), R446Q (RI= 8, DDG= -1.08), G308D (RI= 3, DDG= -0.87), L81F (RI= 7, DDG= -0.76), C342Y (RI= 4, DDG= -0.75), Y460C (RI= 6, DDG= -0.71), L313M (RI= 5, DDG= -0.66), I309T (RI= 2, DDG= -0.66), I309M (RI= 5, DDG= -0.64), Y280D (RI= 2, DDG= -0.24), N457Y (RI= 1, DDG= -0.01) are also predicted to decrease the stability. S155F and T314K were predicted to decrease the stability with values of RI=3, DDG=-0.63 and RI=0, DDG=-0.56, respectively. On the other

hand, the variants C190F (RI= 3, DDG= 0.11), Y220C (RI= 2, DDG= 0.57), T310I (RI= 0, DDG= 0.37), T317S (RI= 2, DDG= 0.12) are predicted to increase the protein stability. However, their DDG values are near to zero and RI values are relatively low suggesting that these variants may not lead to the predicted effects. Thus, in the following steps we will include these variants in addition to other destabilizing variants.




Figure 4. Stability prediction by I-Mutant server[82]. Bar charts showing the RI (A) and DDG values (B) of the 28 nsSNPs. All predicted to decrease stability except one of them (S155F). (RI= reliability index, DDG= Free energy change value, DDG>0 increase in stability, DDG<0 decrease in stability)

3.5. Evolutionary conservation profile of GABRG2 gene variants

Comparing amino acid sequences of homologous proteins can reveal crucial residues, that have likely undergone purifying natural selection, indicating their functional importance and conservation. ConSurf server, which performs a search for closely related homologous sequences [101], was used to identify the highly conserved residues. As presented in the **Figure 5** (and **Appendix C Table 5**), the variants P83T, R125H, D149H, C190F, Y280D, G308D, T310I, L313M, T314K, T317S, Y331N, D336G, C342Y, R446Q, N457Y, Y460C and W461R all share the ConSurf [101] score of 9, that considered to be the most conserved. Furthermore, it was also identified if the residue is a structural or functional residue (**Appendix C Table 5**).




Figure 5. Conservation profile of GABRG2 residues.

Among the most deleterious 28 variants, 20 of them (P83T, R125H, D149H, S155F, C190F, M199T, E217G, Y280D, G308D, T310I, L313M, T314K, T317S, Y331N, D336G, C342Y, R446Q, N457Y, Y460C and W461R) were predicted as highly conserved structural/functional residues (**Appendix C, Table 5**). Among these 20 variants, 3 variants (S155F, M199T and E217G) scored 8 by ConSurf [101] which also indicated them as highly conserved residues. These 20 variants were chosen for further investigation in this study.

3.6. Three-dimensional modeling

The utilization of 3D structural analysis of proteins has important clinical implications [72]. In our research, we identified a notable number of missense variants that were predicted to completely impair protein function. To visualize the effect of these 20 variants on GABRG2 protein structure, the wild-type GABRG2 and its mutant 3D structures were generated using Phyre2 web server [102]. The wild-type sequence and each mutation were run separately to the server. The generated structures were then submitted to the TM-align server [103] to calculate the TM-scores (template modeling scores) and RMSD (root-mean-square deviation) values for each mutant structure in alignment with the wild-type structure (**Appendix C Table 6**). TM-score [104] evaluates topological similarity between wild-type and mutant structures, while RMSD value measure the root-mean-square distance between corresponding atom pairs of the two protein models, to assess the degree of similarity of two protein 3D structures [105]. A higher RMSD value suggests a greater structural difference between the wild-type and mutant forms[105]. TM-score assigns a numeric value ranging from 0 to 1, with 1 signifying an exact match between the two structures. Only structures with highest RMSD (cut off > 3.0) among the lowest TM-scores (cut off < 0.7) were chosen leading to the identification of 10 variants (S155F, C190F, M199T, Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C)

selected to be the most deleterious. The summary of the results identified so far are shown in the **Figure 6**, where 10 the most deleterious variants are highlighted with yellow box.




Figure 6. Graphical representation of the pathogenic variants located in the $\gamma 2$. The diagram (A) showing the distribution and peptide sequence position of the initially identified 28 variants along the $\gamma 2$ subunit in the cell membrane in diagram (B). The variants written in the yellow box in the diagram (A) highlights 10 variants (S155F, C190F, M199T, Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C) representing the most pathogenic. (ECD: N-terminus extracellular domain, M1: First transmembrane domain, M2: Second transmembrane domain, M3: Third transmembrane domain, M4: Fourth transmembrane domain. ICD: Intracellular domain between the third and fourth transmembrane domains, Sig peptide: Signal peptide)

The 3D structures for these 10 variants were regenerated using the I-TASSER [106,107] server, which provides 5 different structures for each entry, with a C-score that ranged from -5 to 2, where a C-score of higher value signifies a model with a high confidence. Then these structures were validated by calculating their overall quality factors using ERRAT server [108] (**Appendix C Table 7**). The structures with highest C-score and highest quality factors variants (>70%, **Appendix C Table 7**) were chosen and visualized by UCSF Chimera 1.17 [109] The structure of these variants (S155F, C190F, M199T, Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C) were superimposed over the wild-type structure to assess the similarity between the two models. The superimposed models are shown in the **Figure 7**. The superimposition of structures indicates whether these models share the same structure and the extent of the differences between them. As shown in **Figure 7**, the wild-type GABRG2 protein structure (represented by the yellow structure) was superimposed with the mutated GABRG2 structures for each mutation separately (shown as colored

structures) and all of them resulted in RMSD values (**Figure 7**), greater than 0.5, indicating significant variations from the wild-type structure. The superimpositions, along with the RMSD values demonstrate that these mutations might significantly affect the structure of the $\gamma 2$ subunit.




Figure 7. $\gamma 2$ subunit three dimensional structures generated by I-TASSER[106,107] and visualized by Chimera [109]. The structures A-J) present the variant amino acid superimposed over the wild-type amino acid (yellow).

3.7. Mapping the variants on to the structural/functional hotspots

As epilepsy research is continuously evolving, new findings shed light on the specific structural and functional alterations in the $\gamma 2$ subunit that is associated with the specific cellular pathology and other characteristics of epilepsy syndromes [27,59,110–115]. Thus we also studied our results from this emerging perspective.

3.7.1. Cellular pathology

Frequent presence of mutants in key structural domains of GABA_AR subunits with shared functional characteristics indicates a link between structure and function[115]. Thus, there exist “epileptogenic structural cassettes” within the GABA_AR subunits [115]. GABA_AR mutations contribute to epilepsy through affecting receptor assembly, trafficking, GABA binding, chloride channel function, and receptor kinetics [116]. These alterations are linked to the mutations in the specific structural domains causing the cellular pathology[115]. For instance, epilepsy mutations in the ECD of the $\gamma 2$ subunit affect receptor assembly, leading to ER retention and decreased surface expression[27]. As a result, the trafficking of $\gamma 2$ -GABA_ARs has emerged as critical in epilepsy, primarily due to frequent alterations in this process, such as inadequate subunit incorporation during assembly in the ER, which poses a limitation to forward trafficking [27,95]. Thus, we predict that pathogenic variants like S155F, C190F, M199T in the ECD will alter receptor assembly, increase ER

retention, and reduce trafficking, surface expression, and GABAergic current. Especially, the variant S155F, being at the interaction interface of $\gamma 2$ subunit with $\beta 2$ & $\beta 3$ subunit (**Appendix C, Table 4**), has the highest possibility for this incidence. Nevertheless, for the $\gamma 2$ subunit, this mechanism appears as a general pathological mechanism for many of the GABRG2 subunit mutations in different domains [27]. As a result, the proposed pathology of all variants i.e., variants in the ECD (S155F, C190F, M199T), variant (Y280D) in the M1, variants (G308D, T310I, T314K, T317S) in the M2, variant (C342Y) in the M3 and the variant Y460C in the M4 would be reduced cell surface expression mostly via the reduced trafficking, increased ER retention, leading to the reduced cell current. Notably, our previous results (**Supplementary File 3, Table 3**) support the findings for the variants T310I, T310I, T314K, T317S in the M2 since these variants are located at the subunit interaction interfaces (**Appendix C, Table 4**). Thus, for the variants (G308D, T310I, T314K, T317S) in the M2, forming the ion channel pore of the receptor [21], alteration in trafficking is expected, in addition to disturbance in the ion channel conductance. These altogether will likely manifest a higher degree of alteration.

3.7.2. Epilepsy phenotype

Studies indicate that the relationship between genotype and epilepsy phenotype, especially in relation to genes that encode ion channels and receptors, is complex [74]. Despite this,

These mutations may be linked to the severity of epilepsy phenotypes [111]. Mutations in the N-terminus extracellular domain (ECD) of the receptor subunits are thought to be linked with milder phenotypes (generalized epilepsy associated with mild to moderate intellectual disability) while mutations in the transmembrane regions (M1-M4) are considered for a more severe early-onset epilepsy, with severe intellectual disability [111]. For instance, patient mutations in the pore-lining M2 region exhibited notably severe phenotypes [91]. Thus, we anticipate that among the predicted pathogenic variants, those in the ECD will manifest milder epilepsy, and transmembrane variants will result in more severe phenotypes. Specifically, we propose that based on the patient mutations described in the literature [115], the variants in the ECD (S155F, C190F, M199T, **Figure 6A**) are predicted to be associated with milder epilepsy phenotypes. The variants in the transmembrane domains (variants in the M2: Y280D, variants in the M2: G308D, T310I, T314K, T317S, variant in the M3: C342Y and variant in the M4: Y460C, **Figure 6A**) are expected to manifest severe epilepsy phenotypes. In our previous paper [117] we described the utility of HPO (The Human Phenotype Ontology) [118] for a discussion of epilepsy phenotype and genetic

variation. This perspective can be used for an extended evaluation of phenotypic severity in relation to variants predicted as pathogenic.

4. Discussion and Conclusion

Our study focused on the prediction of variant impact for a set of non-synonymous single-nucleotide polymorphisms (nsSNPs) with unknown molecular consequence within the coding region of the $\gamma 2$ subunit of GABA_AR. These variants or VUS were subjected to predictive algorithms and the variants identified with highest probability of pathogenicity were validated by protein modeling. We have predicted 10 variants as the most pathogenic. These variants are S155F, C190F, M199T, Y280D, G308D, T310I, T314K, T317S, C342Y, Y460C. These resultant variants were integrated with the data of epilepsy patient mutations mapping the predicted variants on the 'epileptogenic structural cassettes' [115]. Thus, these ten variants are anticipated to contribute to cellular pathology characterized by reduced trafficking, increased endoplasmic reticulum retention and reduced cell current. Further integration of epilepsy patient mutations [111] have led to the presumed phenotype severity as a consequence of variant effect. Among these, the variants in the ECD (S155F, C190F, M199T) are predicted to be associated with milder epilepsy phenotypes. The variants in the transmembrane domains (variants in the M1: Y280D, variants in the M2: G308D, T310I, T314K, T317S, variant in the M3: C342Y and variant in the M4: Y460C) are expected to manifest severe epilepsy phenotypes. Consequently, our integrative approach implies that the specific position of GABRG2 variants might potentially forecast the intensity of clinical features, as also discussed in our previous papers [117].

Our results suggest the powerful utilization of accumulating data to support our comprehensive analysis which has the potential to guide wet lab experimentation and help decision making for differential diagnosis. Differential diagnosis may benefit from neuropathological examination, but neuropathological examination for late onset epilepsy, for instance, does not have definitive guidelines [119]. Genetic testing is another way which might support differential diagnosis but prevalence of VUS is a major challenge. As utilization of genetic testing represents a shift towards a more tailored and individualized approach in managing epilepsy [68], determining whether the VUS are benign or disease-causing requires a thorough assessment of their effects. As a result, the use of computer-based tools to predict the consequences of these variants, known as *in silico* tools, has become indispensable. The ACMG/AMP provide guidelines for variant interpretation, categorizing variants as "Pathogenic", "Likely pathogenic", "Benign", or "Likely benign". *In silico* methods, such as predictive algorithms, are

considered as supporting evidence for pathogenicity, as outlined in criterion PP3 [70]. Thus, our results corresponding to PP3, have implications for the clinical management of epilepsy since it aligns with this framework for the categorization the pathogenic variants. Regarding this, accumulating examples from literature provide evidence for successful integration of the PP3 criterion into the clinical decision making [68] suggesting that our in silico results presenting the presumed pathogenic GABRG2 variants have potential for aiding epilepsy diagnosis and management, especially with the available examples for integrating in silico variant prediction into the diagnostic pathway [120].

There are some limitations of this study. The use of in silico tools and reference sequences may affect prediction accuracy, warranting cautious interpretation. Generalizing from single studies should be avoided. The focus here was on nonsynonymous point mutations in the $\gamma 2$ subunit coding region. However, other variants, like those in splice sites or untranslated regions (UTRs), may play vital roles in epilepsy syndromes or GABA_AR-related channelopathies. Computational findings indicate transcription factor recognition sites in the 5' UTR of GABA_AR subunit genes, suggesting potential impact on subunit expression. Further research should explore rare noncoding region variants in the GABRG2 gene using novel tools and frameworks. Utilizing functional annotation databases and machine learning for transcriptomic profiling can enhance precision medicine. Additionally, in the present study we specifically focused on the identification of pathogenic variants however, variants that might impact the on the ligand binding sites may have consequences for drug response. For instance, there are variants such as Phe343Leu (ClinVar Accession and version number: VCV000205551.2) identified in our study (Appendix B), located at the binding site (PDB 6X3W) of the Phenobarbital[66], an antiseizure medication[64]. Also, this variant overlaps with Diazepam binding site (PDB 6X3X)[34]. Although Phe343Leu was not predicted as pathogenic in our study, it may impact on the Phenobarbital and Diazepam response of the epileptic patients. Similarly, variant Asp336Gly (ClinVar Accession number: VCV000408214.7) overlaps with Diazepam binding site[34]. Although Asp336Gly was not predicted as pathogenic in our study, it may impact on the Diazepam response of the patients medicated by this drug. Thus, conducting docking simulations to study the impact of these variants on ligand binding (e.g., Phenobarbital, Diazepam) is crucial for future research.

Appendices

Appendix A. Material and Method

Appendix B. The summary of ClinVar data for GABRG2, The MutPred2 Analysis Results

Appendix C. Table 1-7 summarizing the results in the relevant sections in the main text.

Acknowledgment

Not applicable

Declaration of Ethical Code

In this study, we undertake that all the rules required to be followed within the scope of the "Higher Education Institutions Scientific Research and Publication Ethics Directive" are complied with, and that none of the actions stated under the heading "Actions Against Scientific Research and Publication Ethics" are not carried out.

Ethical approval

Not applicable

References

- [1] Paulsen O, Moser EI 1998 A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. *Trends Neurosci* 21:273-278
- [2] Klausberger T, Magill PJ, Marton LF, Roberts JDB, Cobden PM, Buzsaki G, Somogyi P 2003 Brain state- and cell type-specific firing of hippocampal interneurons in vivo. *Nature* 421 844–8
- [3] Freund T. F. 2003 Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. *Trends Neurosci.* 26(9) 489–95
- [4] Paille, V., Fino, E., Du, K., Morera-Herreras, T., Perez, S., Kotaleski, J. H., & Venance, L. 2013 GABAergic circuits control spike-timing-dependent plasticity. *J. Neurosci. Off. J. Soc. Neurosci.* 33(22), 9353–9363.
- [5] Klausberger T. 2009 GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus. *Eur. J. Neurosci.* 30(6) 947–57
- [6] Nyíri, G., Freund, T. F., & Somogyi, P. 2001 Input-dependent synaptic targeting of alpha(2)-subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. *Eur. J. Neurosci.* 13(3), 428–442.
- [7] Klausberger T, Roberts JD, Somogyi P 2002 Cell type- and input-specific differences in the number and subtypes of synaptic GABA receptors in the hippocampus. *J Neurosci* 22:2513–2521
- [8] Pawelzik H, Hughes DI, Thomson AM (2002) 2002 Physiological and morphological diversity of immunocytochemically defined parvalbumin- and cholecystokinin-positive

- interneurons in CA1 of the adult rat hippocampus. *J Comp Neurol* **443**:346–367
- [9] Freund, T. F., & Buzsáki, G. 1996 Interneurons of the hippocampus. *Hippocampus* **6** 347–470
- [10] Nusser, Z., Sieghart, W., & Somogyi, P. 1998 Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. *J. Neurosci. Off. J. Soc. Neurosci.* **18**(5), 1693–1703.
- [11] Wei, W., Zhang, N., Peng, Z., Houser, C. R., & Mody, I. (2003). Perisynaptic localization of delta subunit-containing GABA(A) receptors and their activation by GABA spillover in the mouse dentate gyrus. *J. Neurosci. Off. J. Soc. Neurosci.* **23**(33), 10650–10661.
- [12] Arslan, A. Clustering of gamma-aminobutyric acid type A receptors *Period. Eng. Nat. Sci.* **3**(1).
- [13] Arslan A 2021 Extrasynaptic δ -subunit containing GABAA receptors *J. Integr. Neurosci.* **20** 173–84
- [14] Arslan A, Engelhardt J and Wisden W 2014 Cytoplasmic domain of δ subunit is important for the extra-synaptic targeting of GABAA receptor subtypes *J. Integr. Neurosci.* **13** 617–31
- [15] Farrant, M., & Nusser, Z. 2005 Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *6*(3), 215–229. *Nat. Rev. Neurosci.*
- [16] Sente A, Desai R, Naydenova K, Malinauskas T, Jounaidi Y, Miehlung J, Zhou X, Masiulis S, Hardwick S W, Chirgadze D Y, Miller K W and Aricescu A R 2022 Differential assembly diversifies GABAA receptor structures and signalling *Nature* **604** 190–4
- [17] Whiting, P. J., Bonnert, T. P., McKernan, R. M., Farrar, S., Le Bourdellès, B., Heavens, R. P., Smith, D. W., Hewson, L., Rigby, M. R., Sirinathsinghji, D. J., Thompson, S. A., & Wafford, K. A. 1999 Molecular and functional diversity of the expanding GABA-A receptor gene family. *Ann. N. Y. Acad. Sci.* **868** 645–653.
- [18] Arslan, A. 2015 Distinct roles of gamma-aminobutyric acid type A receptor subtypes: A focus on phasic and tonic inhibition. *J. Neurobehav. Sci.* **2** 72–6
- [19] Möhler H. (2006). GABA(A) receptor diversity and pharmacology. *Cell Tissue Res.* **326**(2), 505–516.
- [20] Huang, T. H., Lin, Y. S., Hsiao, C. W., Wang, L. Y., Ajibola, M. I., Abdulmajeed, W. I., Lin, Y. L., Li, Y. J., Chen, C. Y., Lien, C. C., Chiu, C. D., & Cheng, I. H. . 2023 Differential expression of GABAA receptor subunits δ and $\alpha 6$ mediates tonic inhibition in parvalbumin and somatostatin interneurons in the mouse hippocampus. *Front. Cell. Neurosci.* **17**, 1146278.
- [21] Goetz T, Arslan A, Wisden W and Wulff P 2007 GABA(A) receptors: structure and function in the basal ganglia *Prog. Brain Res.* **160** 21–41
- [22] Kim Y S and Yoon B E 2017 Altered GABAergic Signaling in Brain Disease at Various Stages of Life *Exp. Neurobiol.* **26** 122–31
- [23] Als, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T., Naamanka, J., Veerapen, K., Levey, D. F., Bendl, J., Bybjerg-Grauholm, J., Zeng, B., Demontis, D., Rosengren, A., Athanasiadis, G., Bækved-Hansen, M., Qvist, P., Bragi Walters, G., Thorgeirsson, T., ... Børnglum, A. D. 2023 Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. *Nat. Med.* **29**(7) 1832–44
- [24] Mody I 2019 GABAAR Modulator for Postpartum Depression *Cell* **176** 1
- [25] Feng, Y. F., Zhou, Y. Y., & Duan, K. M. 2023 The Role of Extrasynaptic GABA Receptors in Postpartum Depression. *Mol. Neurobiol.*
- [26] Fu X, Wang Y J, Kang J Q and Mu T W 2022 GABAA Receptor Variants in Epilepsy *Epilepsy ed S J Czuczwar* (Exon Publications)
- [27] Lorenz-Guertin J M, Bambino M J and Jacob T C 2018 $\gamma 2$ GABAAR Trafficking and the Consequences of Human Genetic Variation *Front. Cell. Neurosci.* **12** 265
- [28] Stafstrom, C. E., & Carmant, L. 2015 Seizures and epilepsy: an overview for neuroscientists. *Cold Spring Harb. Perspect. Med.* a022426.
- [29] Phulera S, Zhu H, Yu J, Claxton DP, Yoder N, Yoshioka C, Gouaux E. 2018 Cryo-EM structure of the benzodiazepine-sensitive $\alpha 1\beta 1\gamma 2\delta$ trimeric GABAA receptor in complex with GABA. *Elife.* **Jul 25**;7:e39383.
- [30] Zhu S, Noviello C M, Teng J, Walsh R M Jr, Kim J J and Hibbs R E 2018 Structure of a human synaptic GABAA receptor *Nature* **559** 67–72
- [31] Miller PSM,S; Malinauskas T; Kotecha A; Rao S; Chavali S; Colibus LD; Pardon E; Hannan S; Scott S; Sun Z; Frenz B; Klesse G; Li S; Diprose JM; Siebert CA; Esnouf RM; DiMaio F; Tucker SJ; Smart TG; Steyaert J; Badu MM; Sansom MSP; Huiskonen JT; Aricescu AR, Heteromeric GABAA receptor structures in positively-modulated active states. *BioRxiv* 2018
- [32] Masiulis S, Desai R, Uchański T, Serna Martin I, Lavery D, Karia D, Malinauskas T, Zivanov J, Pardon E, Kotecha A, Steyaert J, Miller K W and Aricescu A R 2019 GABAA receptor signalling

- mechanisms revealed by structural pharmacology *Nature* **565** 454–9
- [33] Sun, C., Zhu, H., Clark, S., & Gouaux, E. 2023 Cryo-EM structures reveal native GABAA receptor assemblies and pharmacology. *Nature*, 622(7981), 195–201.
- [34] Kim J J, Gharpure A, Teng J, Zhuang Y, Howard R J, Zhu S, Noviello C M, Walsh R M Jr, Lindahl E and Hibbs R E 2020 Shared structural mechanisms of general anaesthetics and benzodiazepines *Nature* **585** 303–8
- [35] Laverty, D., Desai, R., Uchański, T., Masiulis, S., Stec, W. J., Malinauskas, T., Zivanov, J., Pardon, E., Steyaert, J., Miller, K. W., & Aricescu, A. R. 2019 Cryo-EM structure of the human $\alpha 1\beta 3\gamma 2$ GABAA receptor in a lipid bilayer. *Nature*, **565**(7740), 516–520.
- [36] Kim, J. J., & Hibbs, R. E. 2021 Direct Structural Insights into GABAA Receptor Pharmacology. *Trends Biochem. Sci.* **46**(6), 502–517.
- [37] Essrich C, Lorez M, Benson J A, Fritschy J M and Lüscher B 1998 Postsynaptic clustering of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin *Nat. Neurosci.* **1** 563–71
- [38] Schweizer C, Balsiger S, Bluethmann H, Mansuy I M, Fritschy J M, Mohler H and Lüscher B 2003 The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses *Mol. Cell. Neurosci.* **24** 442–50
- [39] Boileau, A. J., Pearce, R. A., & Czajkowski, C. (2010). 2010 The short splice variant of the gamma 2 subunit acts as an external modulator of GABA(A) receptor function. *J. Neurosci. Off. J. Soc. Neurosci.*
- [40] De Blas A. L. (1996). Brain GABAA receptors studied with subunit-specific antibodies. *Molecular neurobiology*, 12(1), 55–71. 1996 Brain GABAA receptors studied with subunit-specific antibodies. *Blas L* **12** 55–71
- [41] Chandra D, Korpi E R, Miralles C P, Blas A L and Homanics G E 2005 GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines *BMC Neurosci.* **6** 30
- [42] Ren Z, Sahir N, Murakami S, Luellen B A, Earnheart J C, Lal R, Kim J Y, Song H and Luscher B 2015 Defects in dendrite and spine maturation and synaptogenesis associated with an anxious-depressive-like phenotype of GABAA receptor-deficient mice *Neuropharmacology* **88** 171–9
- [43] Reid C A, Kim T, Phillips A M, Low J, Berkovic S F, Luscher B and Petrou S 2013 Multiple molecular mechanisms for a single GABAA mutation in epilepsy *Neurology* **80** 1003–8
- [44] Warner T A, Shen W, Huang X, Liu Z, Macdonald R L and Kang J Q 2016 Differential molecular and behavioural alterations in mouse models of GABRG2 haploinsufficiency versus dominant negative mutations associated with human epilepsy *Hum Mol Genet* **25** 3192–207
- [45] McDonald B J and Moss S J 1994 Differential phosphorylation of intracellular domains of gamma-aminobutyric acid type A receptor subunits by calcium/calmodulin type 2-dependent protein kinase and cGMP-dependent protein kinase *J. Biol. Chem.* **269** 18111–7
- [46] Nani F, Bright D P, Revilla-Sanchez R, Tretter V, Moss S J and Smart T G 2013 Tyrosine phosphorylation of GABAA receptor $\gamma 2$ -subunit regulates tonic and phasic inhibition in the thalamus *J. Neurosci. Off. J. Soc. Neurosci.* **33** 12718–27
- [47] Martenson J S, Yamasaki T, Chaudhury N H, Albrecht D and Tomita S 2017 Assembly rules for GABAA receptor complexes in the brain *eLife* **6** 27443
- [48] Oflaz F E, Son Ç D and Arslan A 2019 Oligomerization and cell surface expression of recombinant GABAA receptors tagged in the δ subunit *J. Integr. Neurosci.* **18** 341–50
- [49] Christie S B, Li R W, Miralles C P, Yang B- and Blas A L 2006 Clustered and non-clustered GABAA receptors in cultured hippocampal neurons *Mol. Cell. Neurosci.* **31** 1–14
- [50] Arslan A, Engelhardt J and Wisden W 2014 Cytoplasmic domain of δ subunit is important for the extra-synaptic targeting of GABAA receptor subtypes *J. Integr. Neurosci.* **13** 617–31
- [51] Alldred M J, Mulder-Rosi J, Lingenfelter S E, Chen G and Lüscher B 2005 Distinct gamma2 subunit domains mediate clustering and synaptic function of postsynaptic GABAA receptors and gephyrin *J. Neurosci. Off. J. Soc. Neurosci.* **25** 594–603
- [52] Connolly CN, Krishek BJ, McDonald BJ, Smart TG, Moss SJ. 1996 Assembly and cell surface expression of heteromeric and homomeric gamma-aminobutyric acid type A receptors. *J Biol Chem* **271** 89–96.
- [53] Arslan, A. 2006 *Specifying molecular determinants of the subcellular targeting of synaptic and extrasynaptic GABA A receptors (Doctoral dissertation)*. (Germany: Ruprecht Karl University of Heidelberg)
- [54] Wu, X., Wu, Z., Ning, G., Guo, Y., Ali, R., Macdonald, R. L., De Blas, A. L., Luscher, B., & Chen, G. 2012 γ -Aminobutyric acid type A

- (GABAA) receptor α subunits play a direct role in synaptic versus extrasynaptic targeting. *J. Biol. Chem.* **287**(33), 27417–27430.
- [55] Ghit A, Assal D, Al-Shami A S and Hussein D E E 2021 GABAA receptors: structure, function, pharmacology, and related disorders *J. Genet. Eng. Biotechnol.* **19** 123
- [56] Olsen R. W. (2018). GABAA receptor: Positive and negative allosteric modulators. *Neuropharmacology*, **136**(Pt A), 10–22.
- [57] Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud'homme J F, Baulac M, Brice A, Bruzzone R and LeGuern E 2001 First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene *Nat. Genet.* **28** 46–8
- [58] Kang J Q, Shen W, Zhou C, Xu D and Macdonald R L 2015 The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration *Nat Neurosci* **18** 988–96
- [59] Shen D, Hernandez C C, Shen W, Hu N, Poduri A, Shiedley B, Rotenberg A, Datta A N, Leiz S, Patzer S, Boor R, Ramsey K, Goldberg E, Helbig I, Ortiz-Gonzalez X R, Lemke J R, Marsh E D and Macdonald R L 2017 De novo GABRG2 mutations associated with epileptic encephalopathies *Brain J. Neurol.* **140** 49–67
- [60] Todd E, Gurba K N, Botzolakis E J, Stanic A K and Macdonald R L 2014 GABAA receptor biogenesis is impaired by the γ 2 subunit febrile seizure-associated mutation, GABRG2(R177G) *Neurobiol. Dis.* **69** 215–24
- [61] Bouthour W, Leroy F, Emmanuelli C, Carnaud M, Dahan M, Poncer J C and Lévi S 2012 A human mutation in Gabrg2 associated with generalized epilepsy alters the membrane dynamics of GABAA receptors *Cereb. Cortex* **22** 1542–53
- [62] Huang X, Hernandez C C, Hu N and Macdonald R L 2014 Three epilepsy-associated GABRG2 missense mutations at the γ +/ β - interface disrupt GABAA receptor assembly and trafficking by similar mechanisms but to different extents *Neurobiol. Dis.* **68** 167–79
- [63] Frugier G, Coussen F, Giraud M F, Odessa M F, Emerit M B, Boué-Grabot E and Garret M 2007 A gamma 2(R43Q) mutation, linked to epilepsy in humans, alters GABAA receptor assembly and modifies subunit composition on the cell surface *J. Biol. Chem.* **282** 3819–28
- [64] Löscher, W., & Rogawski, M. A. 2012 How theories evolved concerning the mechanism of action of barbiturates. *Epilepsia*, 53 Suppl 8, 12–25.
- [65] Richardson R, Petrou S, Bryson A. 2024 Established and emerging GABAA receptor pharmacotherapy for epilepsy *Frontiers in Pharmacology*.
- [66] Kim, J. J., Gharpure, A., Teng, J., Zhuang, Y., Howard, R. J., Zhu, S., Noviello, C. M., Walsh, R. M., Jr, Lindahl, E., & Hibbs, R. E. 2020 Shared structural mechanisms of general anaesthetics and benzodiazepines. *Nature*, **585**(7824), 303–308.
- [67] Scheffer, I. E., Berkovic, S. et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
- [68] Knowles, J. K., Helbig, I., Metcalf, C. S., Lubbers, L. S., Isom, L. L., Demarest, S., Goldberg, E. M., George, A. L., Jr, Lerche, H., Weckhuysen, S., Whittemore, V., Berkovic, S. F., & Lowenstein, D. H. 2022 Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress. *Epilepsia* **63** 2461–75
- [69] Katsonis, P., Wilhelm, K., Williams, A., & Lichtarge, O. 2022 Genome interpretation using in silico predictors of variant impact. *Hum. Genet.* **141**(10) 1549–77
- [70] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody W W, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm H L and Committee A C M G L Q A 2015 Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology *Genet. Med. Off. J. Am. Coll. Med. Genet.* **17** 405–24
- [71] Katsonis P, Wilhelm K, Williams A and Lichtarge O 2022 Genome interpretation using in silico predictors of variant impact *Hum. Genet.* **141** 1549–77
- [72] Caswell R C, Gunning A C, Owens M M, Ellard S and Wright C F 2022 Assessing the clinical utility of protein structural analysis in genomic variant classification: experiences from a diagnostic laboratory *Genome Med.* **14** 77
- [73] Akbar F, Saleh R, Kirmani S, Chand P, Mukhtiar K, Jan F, Kumar R and Ibrahim S 2022 Utility of genetic testing in pediatric epilepsy: Experience from a low to middle-income country *Epilepsy Behav. Rep.* **20** 100575
- [74] Johannesen K M, Nikanorova N, Marjanovic D, Pavbro A, Larsen L H G, Rubboli G and Møller R S 2020 Utility of genetic testing for therapeutic decision-making in adults with epilepsy *Epilepsia* **61** 1234–9

- [75] Landrum M J, Lee J M, Riley G R, Jang W, Rubinstein W S, Church D M and Maglott D R 2014 ClinVar: public archive of relationships among sequence variation and human phenotype *Nucleic Acids Res.* **42** 980–5
- [76] Ng P C and Henikoff S 2003 SIFT: Predicting amino acid changes that affect protein function *Nucleic Acids Res.* **31** 3812–4
- [77] Thomas P D, Campbell M J, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A and Narechania A 2003 PANTHER: a library of protein families and subfamilies indexed by function *Genome Res.* **13** 2129–41
- [78] Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane C R, Lim E P, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley G Q and Lander E S 1999 Characterization of single-nucleotide polymorphisms in coding regions of human genes *Nat. Genet.* **22** 231–8
- [79] Capriotti E, Calabrese R and Casadio R 2006 Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information **22** 2729–34
- [80] Capriotti E, Calabrese R, Fariselli P, Martelli P L, Altman R B and Casadio R 2013 WS-SNPs&GO: a web server for predicting the deleterious effect of human protein variants using functional annotation *BMC Genomics* **3** 6
- [81] Pejaver V, Urresti J, Lugo-Martinez J, Pagel K A, Lin G N, Nam H J, Mort M, Cooper D N, Sebat J, Iakoucheva L M, Mooney S D and Radivojac P 2020 Inferring the molecular and phenotypic impact of amino acid variants with MutPred2 *Nat. Commun.* **11** 5918
- [82] Capriotti E, Fariselli P and Casadio R 2005 I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure *Nucleic Acids Res.* **33** 306–10
- [83] Glaser F, Pupko T, Paz I, Bell R E, Bechor-Shental D, Martz E and Ben-Tal N 2003 ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information **19** 163–4
- [84] Ashkenazy H, Erez E, Martz E, Pupko T and Ben-Tal N 2010 ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids *Nucleic Acids Res.* **38** 529–33
- [85] Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T and Ben-Tal N 2016 ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules *Nucleic Acids Res.* **44** 344–50
- [86] Adzhubei I A, Schmidt S, Peshkin L, Ramensky V E, Gerasimova A, Bork P, Kondrashov A S and Sunyaev S R 2010 A method and server for predicting damaging missense mutations *Nat. Methods* **7** 248–9
- [87] Sigel E and Steinmann M E 2012 Structure, function, and modulation of GABA(A) receptors *J. Biol. Chem.* **287** 40224–31
- [88] Wang, H., Bedford, F. K., Brandon, N. J., Moss, S. J., & Olsen, R. W. 1999 GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton. *Nature* **397(6714)**, 69–72.
- [89] Sayers, E. W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., Chetvernin, V., Church, D. M., DiCuccio, M., Federhen, S., Feolo, M., Fingerman, I. M., Geer, L. Y., Helmberg, W., Kapustin, Y., Landsman, D., Lipman, D. J., Lu, Z., Madden, T. L., Madej, T., ... Ye, J. 2011 Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* D38-D51.
- [90] Stenson P D, Ball E V, Mort M, Phillips A D, Shiel J A, Thomas N S, Abeyasinghe S, Krawczak M and Cooper D N 2003 Human Gene Mutation Database (HGMD): 2003 update *Hum. Mutat.* **21** 577–81
- [91] Mottaz, A., David, F. P., Veuthey, A. L., & Yip, Y. L. 2010 Easy retrieval of single amino-acid polymorphisms and phenotype information using SwissVar. *Bioinforma. Oxf. Engl.* **26(6)**, 851-852.
- [92] Armstrong D R, Berrisford J M, Conroy M J, Gutmanas A, Anyango S, Choudhary P, Clark A R, Dana J M, Deshpande M, Dunlop R, Gane P, Gáborová R, Gupta D, Haslam P, Koča J, Mak L, Mir S, Mukhopadhyay A, Nadzirin N, Nair S and Velankar S 2020 PDBE: improved findability of macromolecular structure data in the PDB consortium *Nucleic Acids Res.* **48** 335–43
- [93] consortium Pdb-K B 2020 PDBE-KB: a community-driven resource for structural and functional annotations *Nucleic Acids Res.* **48** 344–53
- [94] Luscher B, Fuchs T and Kilpatrick C L 2011 GABAA receptor trafficking-mediated plasticity of inhibitory synapses *Neuron* **70** 385–409
- [95] Lorenz-Guertin J M and Jacob T C 2018 GABA type a receptor trafficking and the architecture of synaptic inhibition *Dev. Neurobiol.* **78** 238–70
- [96] Wong, L. W., Tae, H. S., & Cromer, B. A. 2015 Assembly, trafficking and function of $\alpha 1\beta 2\gamma 2$ GABAA receptors are regulated by N-terminal

regions, in a subunit-specific manner. *Journal of neurochemistry*, 134(5), 819–832.

- [97] Lachance-Touchette P, Brown P, Meloche C, Kinirons P, Lapointe L, Lacasse H, Lortie A, Carmant L, Bedford F, Bowie D and Cossette P 2011 Novel $\alpha 1$ and $\gamma 2$ GABAA receptor subunit mutations in families with idiopathic generalized epilepsy *Eur. J. Neurosci.* **34** 237–49
- [98] Draguhn A, Verdorn T A, Ewert M, Seeburg P H and Sakmann B 1990 Functional and molecular distinction between recombinant rat GABAA receptor subtypes by Zn²⁺ *Neuron* **5** 781–8
- [99] Smart T G, Moss S J, Xie X and Haganir R L 1991 GABAA receptors are differentially sensitive to zinc: dependence on subunit composition *Br. J. Pharmacol.* **103** 1837–9
- [100] Kasaragod V B, Mortensen M, Hardwick S W, Wahid A A, Dorovykh V, Chirgadze D Y, Smart T G and Miller P S 2022 Mechanisms of inhibition and activation of extrasynaptic $\alpha\beta$ GABAA receptors *Nature* **602** 529–33
- [101] Glaser F, Pupko T, Paz I, Bell R E, Bechor-Shental D, Martz E and Ben-Tal N 2003 ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information *Bioinformatics* **19** 163–4
- [102] Kelley L A, Mezulis S, Yates C M, Wass M N and Sternberg M J 2015 The Phyre2 web portal for protein modeling, prediction and analysis *Nat. Protoc.* **10** 845–58
- [103] Zhang Y and Skolnick J 2005 TM-align: a protein structure alignment algorithm based on the TM-score *Nucleic Acids Res.* **33** 2302–9
- [104] Zhang, Y., & Skolnick, J. 2004 Scoring function for automated assessment of protein structure template quality. *Proteins*
- [105] Carugo O and Pongor S 2001 A normalized root-mean-square distance for comparing protein three-dimensional structures *Protein Sci. Publ. Protein Soc.* **10** 1470–3
- [106] Roy A, Kucukural A and Zhang Y 2010 I-TASSER: a unified platform for automated protein structure and function prediction *Nat. Protoc.* **5** 725–38
- [107] Yang J and Zhang Y 2015 Protein Structure and Function Prediction Using I-TASSER *Curr. Protoc. Bioinforma.* **52** 5 8 1-5 8 15
- [108] Colovos C and Yeates T O 1993 Verification of protein structures: patterns of nonbonded atomic interactions *Protein Sci. Publ. Protein Soc.* **2** 1511–9
- [109] Pettersen E F, Goddard T D, Huang C C, Couch G S, Greenblatt D M, Meng E C and Ferrin T E 2004 UCSF Chimera—a visualization system for exploratory research and analysis *J. Comput. Chem.* **25** 1605–12
- [110] Hernandez C C, Tian X, Hu N, Shen W, Catron M A, Yang Y, Chen J, Jiang Y, Zhang Y and Macdonald R L 2021 Dravet syndrome-associated mutations in GABRA1, GABRB2 and GABRG2 define the genetic landscape of defects of GABAA receptors *Brain Commun.* **3** 033
- [111] Maillard P Y, Baer S, Schaefer É, Desnoux B, Villeneuve N, Lépine A, Fabre A, Lacoste C, El Chehadeh S, Piton A, Porter L F, Perriard C, Wardé M A, Spitz M A, Laugel V, Lesca G, Putoux A, Ville D, Mignot C and Milh M 2022 Molecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort study, review of literature, and genotype-phenotype correlation *Epilepsia* **63** 2519–33
- [112] Kang J Q and Macdonald R L 2016 Molecular Pathogenic Basis for GABRG2 Mutations Associated With a Spectrum of Epilepsy Syndromes, From Generalized Absence Epilepsy to Dravet Syndrome *JAMA Neurol.* **73** 1009–16
- [113] Yang Y, Niu X, Cheng M, Zeng Q, Deng J, Tian X, Wang Y, Yu J, Shi W, Wu W, Ma J, Li Y, Yang X, Zhang X, Jia T, Yang Z, Liao J, Sun Y, Zheng H, Sun S and Zhang Y 2022 Phenotypic Spectrum and Prognosis of Epilepsy Patients With GABRG2 Variants *Front. Mol. Neurosci.* **15** 809163
- [114] Zou F, McWalter K, Schmidt L, Decker A, Picker J D, Lincoln S, Sweetser D A, Briere L C, Harini C, Undiagnosed Diseases Network M, Marsh E, Medne L, Wang R Y, Leydiker K, Mower A, Visser G, Cuppen I, Gassen K L, Smagt J, Yousaf A and McKnight D 2017 Expanding the phenotypic spectrum of GABRG2 variants: a recurrent GABRG2 missense variant associated with a severe phenotype *J. Neurogenet.* **31** 30–6
- [115] Hernandez C C and Macdonald R L 2019 A structural look at GABAA receptor mutations linked to epilepsy syndromes *Brain Res.* **1714** 234–47
- [116] Mele M, Costa R O and Duarte C B 2019 Alterations in GABAA-Receptor Trafficking and Synaptic Dysfunction in Brain Disorders *Front. Cell. Neurosci.* **13** 77
- [117] Arslan A 2023 Pathogenic variants of human GABRA1 gene associated with epilepsy: A computational approach *Heliyon* **9**
- [118] Köhler S, Gargano M, Matentzoglou N, Carmody L C, Lewis-Smith D, Vasilevsky N A, Danis D, Balagura G, Baynam G, Brower A M, Callahan T J, Chute C G, Est J L, Galer P D, Ganesan S, Griese M, Haimel M, Pazmandi J, Hanauer M, Harris N L

and Robinson P N 2021 The Human Phenotype Ontology in 2021 *Nucleic Acids Res.* **49** 1207–17

- [119] Rácz, A., Galvis-Montes, D. S., Borger, V., Becker, A. J., & Pitsch, J. 2024 Focused review: Clinico-neuropathological aspects of late onset epilepsies: Pathogenesis. *Seizure*, S1059-1311(24)00182-1.
- [120] Trowbridge, S., Poduri, A., & Olson, H. 2021 Early diagnosis and experimental treatment with fenfluramine via the Investigational New Drug mechanism in a boy with Dravet syndrome and recurrent status epilepticus. *Epileptic Disord. Int. Epilepsy J. Videotape* 954–6